Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,933 | -12,959 | -10,064 | -6,280 | -2,810 |
| Depreciation Amortization | 5 | 22 | 17 | 12 | 6 |
| Accounts payable and accrued liabilities | -72 | -314 | -516 | -704 | -350 |
| Other Working Capital | 126 | -1,055 | -347 | -1,473 | -1,162 |
| Other Operating Activity | 242 | 749 | 864 | 867 | 380 |
| Operating Cash Flow | $-3,631 | $-13,557 | $-10,046 | $-7,578 | $-3,936 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -16 | -16 | -16 | -8 |
| Investing Cash Flow | $N/A | $-16 | $-16 | $-16 | $-8 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 59 | 16,140 | 16,000 | 16,000 | N/A |
| Other Financing Activity | -3 | -1,319 | -1,312 | -1,311 | 14,710 |
| Financing Cash Flow | $56 | $14,822 | $14,688 | $14,689 | $14,710 |
| Exchange Rate Effect | 1 | -7 | 17 | -7 | -2 |
| Beginning Cash Position | 22,890 | 21,648 | 21,648 | 21,648 | 21,648 |
| End Cash Position | 19,316 | 22,890 | 26,291 | 28,736 | 32,411 |
| Net Cash Flow | $-3,575 | $1,250 | $4,644 | $7,088 | $10,763 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,631 | -13,557 | -10,046 | -7,578 | -3,936 |
| Capital Expenditure | N/A | -16 | -16 | -16 | -8 |
| Free Cash Flow | -3,631 | -13,572 | -10,061 | -7,593 | -3,944 |